Pharma stocks in India witnessed a sharp uptick on May 13, following a relief rally after former U.S. President Donald Trump\u2019s executive order on drug pricing turned out to be less severe than initially feared.<\/p>\n
While the broader market was under pressure \u2014 with benchmark indices trading nearly 1% lower \u2014 the Nifty Pharma index defied the trend and was trading 1.3% higher. This surge came on the back of global cues as investors responded positively to Trump\u2019s latest comments on reducing drug prices.<\/p>\n
On May 12, Donald Trump announced a significant policy move aimed at cutting domestic drug prices in the U.S. He proposed reductions ranging between 30% to 80%, and later clarified that a 59% cut would be pursued under the executive order.<\/p>\n
He emphasized this policy on his social media platform, writing in capital letters: \u201cDRUG PRICES TO BE CUT BY 59%\u201d. The executive order is based on the \u201cmost favored nation\u201d pricing model, also known as international reference pricing. This means the U.S. would aim to pay prices similar to what other developed nations pay for the same medications.<\/p>\n
Despite the aggressive language, analysts pointed out that the final version of the executive order was far more diluted compared to Trump\u2019s earlier 2020 proposals. According to a note by Macquarie Capital (as reported by CNBC-TV18), this reduced intensity came as a relief for investors who were bracing for a much harsher clampdown on pricing.<\/p>\n
The positive sentiment lifted several Indian pharma stocks:<\/p>\n
Granules India emerged as the top gainer, rallying 4% to trade at \u20b9479 per share.<\/p>\n<\/li>\n
Aurobindo Pharma climbed 3.4% to \u20b91,247 apiece.<\/p>\n<\/li>\n
Glenmark Pharmaceuticals saw a 3% rise, trading at \u20b91,423.<\/p>\n<\/li>\n
Dr. Reddy\u2019s Laboratories was up 2%, quoted at \u20b91,220.<\/p>\n<\/li>\n
Sun Pharma saw a modest gain of 0.64% during the same time.<\/p>\n<\/li>\n<\/ul>\n
Investors responded positively to the softened stance, interpreting it as a signal that Indian drug exporters \u2014 many of whom rely on the U.S. for a significant share of revenues \u2014 would not face the kind of pricing pressure they feared.<\/p>\n
The impact of this development wasn\u2019t limited to Indian markets. Major U.S. pharma companies also staged a strong recovery after an initial dip in premarket trading:<\/p>\n
Merck & Co surged 5.8%<\/p>\n<\/li>\n
Pfizer gained 3.6%<\/p>\n<\/li>\n
Gilead Sciences jumped 7.1%<\/p>\n<\/li>\n
Eli Lilly, the largest drugmaker by market cap, rose 2.9%<\/p>\n<\/li>\n<\/ul>\n
This global rally indicates a broad consensus among investors that Trump\u2019s order, while impactful, does not pose an immediate threat to the profitability of drug manufacturers.<\/p>\n
The reaction from the stock market clearly shows that investors were bracing for worse. The softer execution of the \u201cmost favored nation\u201d pricing model has offered temporary relief to pharma companies with U.S. exposure \u2014 particularly Indian exporters who count on America as a major market.<\/p>\n
With pharma stocks outperforming even in a falling market, it’s clear that this sector remains resilient and continues to attract investor interest, especially during times of global policy shifts.<\/p>\n
\n","protected":false},"excerpt":{"rendered":"
Pharma stocks in India witnessed a sharp uptick on May 13, following a relief rally after former U.S. President Donald Trump\u2019s executive order on drug pricing turned out to be less severe than initially feared. While the broader market was under pressure \u2014 with benchmark indices trading nearly 1% lower \u2014 the Nifty Pharma index […]<\/p>\n","protected":false},"author":2,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[615],"tags":[],"ppma_author":[1329],"class_list":{"0":"post-8538","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stock-market-news"}," _eael_post_view_count":0,"authors":[{"term_id":1329,"user_id":2,"is_guest":0,"slug":"snehagandhi","display_name":"Sneha Gandhi","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/10\/Sneha-Gandhi.jpeg","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/10\/Sneha-Gandhi.jpeg"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/8538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=8538"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/8538\/revisions"}],"predecessor-version":[{"id":8540,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/8538\/revisions\/8540"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/8539"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=8538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=8538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=8538"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=8538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}